Navigation Links
Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
Date:2/20/2008

geting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, planned clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of preclinical studies or clinical trials may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required u
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
2. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
3. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
4. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
5. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
6. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
9. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... 10 With the economy and markets exhibiting ... largest, fastest-growing small cap equity research provider, will seek ... opportunities within the micro cap market at the firm,s ... 11, 2010 at the Grand Hyatt Hotel in New ... overlooked and undervalued by much of Wall Street, but ...
(Date:12/10/2009)... Brooks Instrument, a world-leading provider of advanced flow ... Bayda will join the company as Global Level ... lead Brooks Instrument’s efforts to enhance market penetration ... He is joining Brooks Instrument from Lafarge Corp, ... as Director of Marketing and Sales. Bayda will ...
(Date:12/10/2009)... 10 /PRNewswire-Asia/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin ... growing developer and,producer of prescription drugs and ... People,s Republic of China ("PRC"), today reported ... controlled operating entity of Lotus,appointed Mr. Jinzhong ... Company,s,Over-the-Counter Drug division ("OTC Division"). , ...
(Date:12/10/2009)... Dendreon Corporation (Nasdaq: DNDN ) today ... chief operating officer, effective January 4, 2010. Mr. ... medicine business at Bayer, where he was responsible for ... Mr. Bishop also served as an executive vice ... member of the Dendreon executive management team, Mr. Bishop ...
Breaking Biology Technology:Technology, Biotech, Energy and Transportation Among the Industries to be Featured at Sidoti & Company's First Annual 2010 Micro Cap Conference 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Dendreon Appoints Hans Bishop as Chief Operating Officer 2
... Silence Therapeutics plc (London AIM:,SLN), a leading ... reasons, Jeffery Vick has resigned as Group CEO ... has appointed Iain Ross, currently Non-Executive,Chairman, full time ... Cook, a Non-Executive Director of the Company has ...
... ,Hologic, Inc. (Nasdaq: HOLX ) and Third Wave ... expiration of the initial,offering period of the tender offer ... all outstanding shares of common stock of,Third Wave. The ... York City time, on Wednesday, July 16, 2008., ...
... on Strategies to Promote Legislative Pathway for ... Follow-On ... developer of follow-on biologics and biopharmaceuticals for unmet,medical needs, today announced ... Means Committee from 2001 to 2007, has been,retained by Insmed as ...
Other Biology Technology:Organizational Changes at Silence Therapeutics 2Organizational Changes at Silence Therapeutics 3Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 2Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 3Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 4Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period 5Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 2Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 3Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor 4
(Date:12/14/2009)... from the Astrobiology Centre (INTA-CSIC) has shown that hydrogen ... formation of the most basic biological molecules can be ... carry out this study, published in the journal ... conditions of the early Earth. , "We have shown ... it produces hydrogen cyanide, a substance that could have ...
(Date:12/13/2009)... help to engineer plants that take advantage of elevated ... could help to engineer crops that take advantage of ... dioxide they need for photosynthesis through microscopic breathing pores ... of the gas gained, they lose hundreds of water ... to save water when CO 2 is abundant, ...
(Date:12/11/2009)... "green" trend, educators worldwide are relying more ... science knowledge. Studies have revealed that bringing ... just science scoresenvironmental-based lessons can also improve ... Naturally, educators are interested in developing new ... the classroom in hopes of piquing student ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 2Newly identified enzymes help plants sense elevated CO2 and could lead to water-wise crops 3Students learn environmental stewardship, improve science scores 2Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 1Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 2Remarks As Prepared for Delivery by Attorney General Eric Holder at the Heat Press Conference on Detroit Takedown 49965 3KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER C6 28R 29 12774 1KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER C6 28R 29 12774 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 1Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 2Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 3Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 4Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36 25 Sales Increase 16 25 12772 5
... Census of Marine Life-affiliated scientists consolidating world databases ... almost one-third of all names culled from 34 ... World Register of Marine Species ( www.marinespecies.org ) ... having recognized and tidied up some 56,400 aliases ...
... professor of psychology at UC Santa Barbara and director ... Mind, has received the Humboldt Research Prize in recognition ... a true pioneer in reaching across the disciplines to ... and brain," said UCSB Chancellor Henry T. Yang. "The ...
... growing up in Brooklyn, NY, UC Riverside,s Jerome Schultz ... to peer into a microscope to examine slides of tissues ... years, that early interest in science evolved into an illustrious ... that the American Institute of Chemical Engineers ( AIChE ...
Other Biology News:Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 2Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 3Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 4Census of Marine Life lists 122,500 known species, over halfway to complete inventory by Oct. 2010 5Neuroscientist Michael Gazzaniga awarded Humboldt Prize 2UC Riverside bioengineer receives high honor from chemical engineers 2UC Riverside bioengineer receives high honor from chemical engineers 3UC Riverside bioengineer receives high honor from chemical engineers 4
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
... Recognizes Nabeta2. The epitope specific ... in any other known proteins.,SPECIES ... to work on human because ... conserved (17/19 residues). Reactivity with ...
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Biology Products: